PPP1R1B

Protein phosphatase 1 regulatory subunit 1B · Q9UD71 · PPP1R1B on Sugi Atlas →

0 patent compounds predicted against PPP1R1B, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PPP1R1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer PHASE1/PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Open-label Study on Treatment of Primary Aldosteronism With Everolimus PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery PHASE1COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability PHASE1COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors PHASE1WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Severe Insulin Resistance in Patients With Type 2 Diabetes nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PPP1R1B binder may also engage these)

ProteinNameSimilarity
Q60829 1.000 Q60829 →
P07516 0.999 P07516 →
Q6J4I0 0.998 Q6J4I0 →
Q29277 0.990 Q29277 →
Q0X0E2 0.984 Q0X0E2 →
Q5PR69 0.983 Q5PR69 →
Q5FVJ4 0.983 Q5FVJ4 →
Q8K3I4 0.983 Q8K3I4 →
Q8NC24 0.982 Q8NC24 →
Q6ZU35 0.982 Q6ZU35 →
Q32LQ1 0.981 Q32LQ1 →
A2A9T0 0.981 A2A9T0 →
Q9DBR2 0.980 Q9DBR2 →
Q5T7N3 0.979 Q5T7N3 →
Q07266 0.979 Q07266 →
Q8BRJ3 0.979 Q8BRJ3 →
Q924S9 0.979 Q924S9 →
Q8BFW3 0.978 Q8BFW3 →
Q8VC31 0.978 Q8VC31 →
Q2KI80 0.978 Q2KI80 →
Q96MH2 0.978 Q96MH2 →
Q6P9J5 0.978 Q6P9J5 →
DBN1 Drebrin 0.978 landscape →
Q5XKK7 0.978 Q5XKK7 →
Q5BJM5 0.977 Q5BJM5 →
Q64327 0.977 Q64327 →
Q0II70 0.977 Q0II70 →
Q6PJ61 0.977 Q6PJ61 →
Q96MK2 0.977 Q96MK2 →
Q16626 0.977 Q16626 →